Lung Cancer ScreeningNCT07639255
Kentucky - Quality Improvement Implementation Lung Cancer Screening (QUILS™) Implementation
A study testing QUILS System in people with Lung Cancer Screening, run by Timothy Mullett at 17 sites in United States.
Trial summary
This is an optimization pathway for lung cancer screening programs. Enrolled programs will undergo an audit for elements associated with improved quality and retention of patients in the screening process. A feedback report is delivered to identify priorities for process improvement. Read more about this study
- Who is it for?
- Ages 18 to 100 years
- Conditions the study is for
- Lung Cancer Screening
- What is being tested?
- QUILS System
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 330 participants
- Where
- 17 sitesUnited States
- Study dates
- 1 Apr 2025to 1 Jun 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 100 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Participants in Lung Cancer Screening Program, including physicians, nurses, administrators and other staff responsible for the conduct of the program.
- Willing to participate in the QUILS Index Assessment Survey process
- Willing to participate in the QUILS Audit Feedback presentations Willing to participate in formative evaluation interviews
Who cannot join
- Unwilling to participate in the QUILS Index Assessment Survey process
- Unwilling to participate in the QUILS Audit Feedback presentations
- Unwilling to participate in formative evaluation interviews
Trial locations and contacts
17 sites in 1 country. Contact the study team or a site near you to ask about taking part.
17 sites in 1 country
United States17 sites, 17 recruiting
- Recruiting
King's Daughter's Medical Center
Ashland, Kentucky, 41101
Joseph Alexander, 8593230892, joseph.alexander@uky.edu
- Recruiting
Taylor Regional Hospital
Campbellsville, Kentucky, 42718
Joseph Alexander, 8593230892, joseph.alexander@uky.edu
- Recruiting
St. Elizabeth Healthcare
Edgewood, Kentucky, 41017
Joseph Alexander, 8593230892, joseph.alexander@uky.edu
- Recruiting
Georgetown Cancer Treatment Cancer
Georgetown, Kentucky, 40324
Joseph Alexander, 8593230892, joseph.alexander@uky.edu
- Recruiting
TJ Samson Community Hospital
Glasgow, Kentucky, 42141
Joseph Alexander, 8593230892, joseph.alexander@uky.edu
- Recruiting
Hazard Appalachian Regional Healthcare Medical Center
Hazard, Kentucky, 41701
Joseph Alexander, 8593230892, joseph.alexander@uky.edu
- Recruiting
Lexington VA Health Care System
Lexington, Kentucky, 40502
Joseph Alexander, 8593230892, joseph.alexander@uky.edu
- Recruiting
St. Joseph Health (Catholic Health Initiatives)
Lexington, Kentucky, 40504
Joseph Alexander, 8593230892, joseph.alexander@uky.edu
- Recruiting
University of Kentucky Markey Cancer Center
Lexington, Kentucky, 40536
Joseph Alexander, 8593230892, joseph.alexander@uky.edu
- Recruiting
The James Graham Brown Cancer Center at University of Louisville
Louisville, Kentucky, 40202
Joseph Alexander, 8593230892, joseph.alexander@uky.edu
- Recruiting
Meadowview Regional Medical Center
Maysville, Kentucky, 41056
Joseph Alexander, 8593230892, joseph.alexander@uky.edu
- Recruiting
Saint Claire Regional Medical Center
Morehead, Kentucky, 40351
Joseph Alexander, 8593230892, joseph.alexander@uky.edu
- Recruiting
Rockcastle Regional Hospital
Mount Vernon, Kentucky, 40456
Jospeh Alexander, 8593230892, joseph.alexander@uky.edu
- Recruiting
Owensboro Health Mitchell Memorial Cancer Center
Owensboro, Kentucky, 42303
Joseph Alexander, 8593230892, joseph.alexander@uky.edu
- Recruiting
Mercy Health - Paducah Cancer Center
Paducah, Kentucky, 42003
Joseph Alexander, 8593230892, joseph.alexander@uky.edu
- Recruiting
Lake Cumberland Regional Hospital
Somerset, Kentucky, 42501
Joseph Alexander, 8593230892, joseph.alexander@uky.edu
- Recruiting
Clark Regional Medical Center
Winchester, Kentucky, 40391
Joseph Alexander, 8593230892, joseph.alexander@uky.edu
About this study
Official title: Statewide Optimization of Lung Cancer Screening Utilizing the QUILS System
This is an optimization pathway for lung cancer screening programs. Enrolled programs will undergo an audit for elements associated with improved quality and retention of patients in the screening process. A feedback report is delivered to identify priorities for process improvement.
- Conditions
- Lung Cancer Screening
- Being tested
- QUILS System
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
QUILS SystemOther
Implementation initiative involving statewide coalition engagement surveys, interviews, educational outreach, and collaborative activities designed to improve awareness, coordination, policy support, and implementation of equitable and high-quality lung screening programs.
| Study group | Role | What they receive |
|---|---|---|
| QUILS Kentucky Coalition Initative | Other | Not described Receives: Other: QUILS System |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Quality Improvement Lung Cancer Screening (QUILS) Index Assessment Score
The QUILS Index Assessment is a program-level measure of lung cancer screening implementation quality. Scores range from 0 to 95, with a higher score indicating higher quality implementation of lung cancer screening practices. The outcome measure is the change in total QUILS Index score from Baseline to 12 months.
Measured: One year following study start up and initial assessment.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Jun 2026
- Study start1 Apr 2025
- Primary completion1 Jun 2027 (estimated)
- Study completion1 Jun 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Lung Cancer ScreeningStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Screening
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 330 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Timothy Mullett
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Timothy Mullett, University of Kentucky
- Investigators
- Timothy W Mullett, MD, Study chair, University of Kentucky
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07639255
- Sponsor's protocol ID
- MCC-25-KYQUILS-MD
- Status last verified
- Jun 2026
- First submitted
- 5 Jun 2026
- Last updated
- 1 Jul 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 1 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Statewide Optimization of Lung Cancer Screening Utilizing the QUILS System
- ClinicalTrials.gov ID
- NCT07639255
- Acronym / sponsor ID
- MCC-25-KYQUILS-MD
- Conditions
- Lung Cancer Screening
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 330 participants (estimated)
- Lead sponsor
- Timothy MullettUniversity, hospital or other
- Study start
- 1 Apr 2025 (actual)
- Primary completion
- 1 Jun 2027 (estimated)
- Study completion
- 1 Jun 2028 (estimated)
- First posted
- 10 Jun 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is an optimization pathway for lung cancer screening programs. Enrolled programs will undergo an audit for elements associated with improved quality and retention of patients in the screening process. A feedback report is delivered to identify priorities for process improvement.
Study design
- Primary purpose
- Screening
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| QUILS Kentucky Coalition Initative | Other | Other: QUILS System |
Who may qualify
- Ages
- 18 to 100 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Participants in Lung Cancer Screening Program, including physicians, nurses, administrators and other staff responsible for the conduct of the program.
- Willing to participate in the QUILS Index Assessment Survey process
- Willing to participate in the QUILS Audit Feedback presentations Willing to participate in formative evaluation interviews
Key exclusion criteria (3 listed)
- Unwilling to participate in the QUILS Index Assessment Survey process
- Unwilling to participate in the QUILS Audit Feedback presentations
- Unwilling to participate in formative evaluation interviews
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| QUILS SystemImplementation initiative involving statewide coalition engagement surveys, interviews, educational outreach, and collaborative activities designed to improve awareness, coordination, policy support, and implementation of equitable and high-quality lung screening programs. | Other | QUILS Kentucky Coalition Initative |
Primary outcome
Change in Quality Improvement Lung Cancer Screening (QUILS) Index Assessment Score
Time frame: One year following study start up and initial assessment.
The QUILS Index Assessment is a program-level measure of lung cancer screening implementation quality. Scores range from 0 to 95, with a higher score indicating higher quality implementation of lung cancer screening practices. The outcome measure is the change in total QUILS Index score from Baseline to 12 months.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Jul 2026.
Related trials for Lung Cancer Screening
Active, not recruitingEarly Phase 1
Smoking Cessation Intervention During Low Dose CT (LDCT) Screening for Lung Cancer
Smoking Cessation
Not yet recruiting
C-Raven LDCT: Lung Cancer Screening Intervention
Lung Cancer Screening
Not yet recruitingObservational study
Clinical Genetics Branch Eligibility Screening Survey
Melanoma, Li-Fraumeni Syndrome
Enrolling by invitationObservational study
Screening for Hematology Branch Protocols
Hematologic Disease and Disorders, Donors
Recruiting
A Restorative Justice-Based Lung Cancer Screening Decision-Making Support Intervention Tailored for Black Individuals to Increase Lung Cancer Screening Among Black Community Members, RESTORE Trial
Lung Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Timothy W Mullett, MD study chair
University of Kentucky
17 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing QUILS System in people with Lung Cancer Screening, run by Timothy Mullett at 17 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 1 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 17 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Joseph Alexander, MD (8593230892, joseph.alexander@uky.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Quality Improvement Lung Cancer Screening (QUILS) Index Assessment Score (time frame: One year following study start up and initial assessment.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Jul 2026.